DocGo Inc. — Form 8-K Summary
Reporting event: October 1, 2026. Filed October 5, 2026. The filing reports a new credit agreement, related security and warrant arrangements, termination of an undrawn revolver, and commencement of management services for Hicuity Health. It does not report operating results for a fiscal quarter or year.
Business context and transaction
DocGo’s subsidiary Ambulnz and Hicuity entered into a merger agreement on August 16, 2026; the merger remained pending as of this filing. Effective October 1, 2026, after conditions were satisfied, Ambulnz began managing Hicuity’s day-to-day non-clinical operations under a consulting agreement. Ambulnz will fund Hicuity operating expenses when its operating account is insufficient and receive a weekly fee based on gross revenue collections less operating expenses. The consulting agreement ends at merger closing or termination of the merger agreement, whichever occurs first.
Financing and other key terms
- Credit facilities: The amended and restated agreement continues $52 million of existing term loans (Term Loan A) and provides a $12.5 million Term Loan B to be funded on the agreement’s effective date. It also provides for $12.5 million of Term Loan C upon merger closing, or later at DocGo’s option, and a $25 million delayed-draw Term Loan D available from closing through December 31, 2027, subject to conditions.
- Potential facility size: The listed facilities total up to $102 million, including the continued $52 million balance and conditional or delayed-draw amounts. The filing does not state how much of the new or delayed-draw facilities was ultimately funded beyond the stated funding terms.
- Interest and maturity: Term loans bear interest at Term SOFR, subject to a 3.50% floor, plus 7.50%. No scheduled principal payments are due before maturity; outstanding principal and accrued interest are due December 6, 2029.
- Collateral and guarantees: Borrower obligations are jointly and severally guaranteed by specified guarantors. Grantors pledged a first-priority security interest in substantially all personal property, subject to customary exclusions.
- Warrant: DocGo issued the administrative agent a fully vested warrant for up to 4 million common shares at $0.5039 per share. It is exercisable for 10 years from October 1, 2026, with automatic exercise in specified circumstances. DocGo reported 98,992,347 common shares outstanding as of October 1, 2026.
- Prior revolver: DocGo terminated its August 2025 revolving credit facility before entering the new agreement. Its commitments were undrawn, and related guarantees and liens were released.
Financial performance and changes
This 8-K provides no revenue, profit, cash flow, margin, or liquidity metrics and no comparable-period financial results. It does not quantify cash proceeds or fees associated with the new financing. The principal reported financing change is the replacement of an undrawn revolving facility with term-loan financing, including additional funding tied to the Hicuity merger and a delayed-draw facility.
Risks, contingencies, and unusual items
- The credit agreement includes financial and other covenants, restrictions on additional debt, liens, acquisitions, investments, asset sales, and restricted payments, with customary exceptions.
- Defaults may allow lenders to terminate commitments and accelerate amounts due; bankruptcy or insolvency defaults cause automatic termination and acceleration. Accelerated loans may include a prepayment premium.
- Mandatory prepayments may be triggered by specified casualty events, impermissible indebtedness, or asset sales, subject to thresholds and reinvestment rights. Optional prepayments are subject to a premium.
- Stock repurchases are generally restricted. DocGo may repurchase up to $40 million under its existing program only with administrative-agent consent, pro forma covenant compliance, and no continuing default.
- The warrant creates potential share dilution. The filing’s Item 3.02 says the warrant was “issued to the Company,” while Item 1.01 describes DocGo as issuing it to the administrative agent; investors should verify the intended recipient in the warrant exhibit.
- No management outlook, guidance, or quantified assessment of the merger’s expected financial impact is provided.
Important facts for investors to verify
- Funding status and outstanding balances for Term Loans B, C, and D, and the conditions governing future draws.
- Merger closing status and the duration, funding obligations, and economics of Ambulnz’s Hicuity management arrangement.
- Full credit-agreement terms, including financial covenants, prepayment premiums, and any restrictions affecting DocGo’s liquidity or repurchase program.
- Warrant recipient, exercise mechanics, and potential dilution, by reviewing Exhibit 10.3.
- Whether the new financing changes DocGo’s consolidated debt, interest expense, or liquidity; those effects are not quantified in this 8-K.